Page last updated: 2024-08-22

acetylglucosamine and Glomerulosclerosis, Focal Segmental

acetylglucosamine has been researched along with Glomerulosclerosis, Focal Segmental in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Inoue, H; Takeuchi, M; Yamagishi, S	1

Other Studies

1 other study(ies) available for acetylglucosamine and Glomerulosclerosis, Focal Segmental

Article	Year
Olmesartan medoxomil, a newly developed angiotensin II type 1 receptor antagonist, protects against renal damage in advanced glycation end product (age)-injected rats. Drugs under experimental and clinical research, 2005, Volume: 31, Issue:2 Topics: Acetylglucosamine; Angiotensin II Type 2 Receptor Blockers; Animals; Body Weight; Glomerulosclerosis, Focal Segmental; Glycation End Products, Advanced; Imidazoles; Kidney Diseases; Male; Olmesartan Medoxomil; Proteinuria; Rats; Rats, Sprague-Dawley; Receptor Cross-Talk; Renin-Angiotensin System; Tetrazoles; Tissue Fixation	2005

Article

Year

Olmesartan medoxomil, a newly developed angiotensin II type 1 receptor antagonist, protects against renal damage in advanced glycation end product (age)-injected rats.

Drugs under experimental and clinical research, 2005, Volume: 31, Issue:2

Topics: Acetylglucosamine; Angiotensin II Type 2 Receptor Blockers; Animals; Body Weight; Glomerulosclerosis, Focal Segmental; Glycation End Products, Advanced; Imidazoles; Kidney Diseases; Male; Olmesartan Medoxomil; Proteinuria; Rats; Rats, Sprague-Dawley; Receptor Cross-Talk; Renin-Angiotensin System; Tetrazoles; Tissue Fixation

2005